Skip to main content
Erschienen in: Current Treatment Options in Cardiovascular Medicine 6/2012

01.12.2012 | Valvular Heart Disease (AS Desai and PT O’Gara, Section Editors)

Management of Peripartum Cardiomyopathy

verfasst von: Garrick C. Stewart, MD

Erschienen in: Current Treatment Options in Cardiovascular Medicine | Ausgabe 6/2012

Einloggen, um Zugang zu erhalten

Opinion statement

Peripartum cardiomyopathy is diagnosed in women who develop systolic heart failure in the last month of pregnancy or within 5 months of delivery. This diagnosis should not be made in women with pre-existing cardiac disease or another cause of cardiac dysfunction. To prevent delay in diagnosis and treatment, a high index of suspicion is required given the overlapping symptoms of late pregnancy and heart failure. Traditional heart failure medical therapies are indicated, although drugs must be carefully reviewed for safety during pregnancy and lactation. Long-term prognosis is largely determined by the degree of ventricular recovery. Patients with acute or persistent hemodynamic compromise despite medical therapy should be considered for mechanical circulatory support and evaluated promptly for cardiac transplantation. A multidisciplinary team is required to care for patients with peripartum cardiomyopathy through parturition and beyond. All peripartum cardiomyopathy patients should be counseled that repeat pregnancy can negatively impact cardiac function and lead to recurrent heart failure or even death. Patients with persistent ventricular dysfunction should be strongly advised against another pregnancy.
Literatur
1.
Zurück zum Zitat Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000;283:1183–8.PubMedCrossRef Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000;283:1183–8.PubMedCrossRef
2.
Zurück zum Zitat Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12:767–78.PubMedCrossRef Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010;12:767–78.PubMedCrossRef
3.
Zurück zum Zitat Demakis JG, Rahimtoola SH, Sutton GC, et al. Natural course of peripartum cardiomyopathy. Circulation. 1971;44:1053–61.PubMedCrossRef Demakis JG, Rahimtoola SH, Sutton GC, et al. Natural course of peripartum cardiomyopathy. Circulation. 1971;44:1053–61.PubMedCrossRef
4.
Zurück zum Zitat Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol. 2011;58:659–70.PubMedCrossRef Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J Am Coll Cardiol. 2011;58:659–70.PubMedCrossRef
5.•
Zurück zum Zitat Tanous D, Siu SC, Mason J, et al. B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol. 2010;56:1247–53. This study shows that many pregnant women with heart disease have an elevated BNP and that low BNP has excellent negative predictive value for cardiac events.PubMedCrossRef Tanous D, Siu SC, Mason J, et al. B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol. 2010;56:1247–53. This study shows that many pregnant women with heart disease have an elevated BNP and that low BNP has excellent negative predictive value for cardiac events.PubMedCrossRef
6.
Zurück zum Zitat Mielniczuk LM, Williams K, Davis DR, et al. Frequency of peripartum cardiomyopathy. Am J Cardiol. 2006;97:1765–8.PubMedCrossRef Mielniczuk LM, Williams K, Davis DR, et al. Frequency of peripartum cardiomyopathy. Am J Cardiol. 2006;97:1765–8.PubMedCrossRef
7.
Zurück zum Zitat Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc. 2005;80:1602–6.PubMedCrossRef Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc. 2005;80:1602–6.PubMedCrossRef
8.
Zurück zum Zitat Brar SS, Khan SS, Sandhu GK, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol. 2007;100:302–4.PubMedCrossRef Brar SS, Khan SS, Sandhu GK, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol. 2007;100:302–4.PubMedCrossRef
9.
Zurück zum Zitat Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyopathy in Africa. Circulation. 2005;112:3577–83.PubMedCrossRef Sliwa K, Damasceno A, Mayosi BM. Epidemiology and etiology of cardiomyopathy in Africa. Circulation. 2005;112:3577–83.PubMedCrossRef
10.
Zurück zum Zitat Gentry MB, Dias JK, Luis A, Patel R, Thornton J, Reed GL. African-American women have a higher risk for developing peripartum cardiomyopathy. J Am Coll Cardiol. 2010;55:654–9.PubMedCrossRef Gentry MB, Dias JK, Luis A, Patel R, Thornton J, Reed GL. African-American women have a higher risk for developing peripartum cardiomyopathy. J Am Coll Cardiol. 2010;55:654–9.PubMedCrossRef
11.•
Zurück zum Zitat Gunderson EP, Croen LA, Chiang V, Yoshida CK, Walton D, Go AS. Epidemiology of peripartum cardiomyopathy: incidence, predictors, and outcomes. Obstet Gynecol. 2011;118:583–91. A contemporary look at the risk factors and outcomes with PPCM in a large, diverse population from the United States, highlighting poor neonatal outcomes in PPCM.PubMedCrossRef Gunderson EP, Croen LA, Chiang V, Yoshida CK, Walton D, Go AS. Epidemiology of peripartum cardiomyopathy: incidence, predictors, and outcomes. Obstet Gynecol. 2011;118:583–91. A contemporary look at the risk factors and outcomes with PPCM in a large, diverse population from the United States, highlighting poor neonatal outcomes in PPCM.PubMedCrossRef
12.
Zurück zum Zitat Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128:589–600.PubMedCrossRef Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007;128:589–600.PubMedCrossRef
13.••
Zurück zum Zitat Patten IS, Rana S, Shahul S, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012;485:333–8. An important translational study showing that PPCM is primarily a vascular disease produced by an anti-angiogenic environment in late pregnancy..PubMedCrossRef Patten IS, Rana S, Shahul S, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012;485:333–8. An important translational study showing that PPCM is primarily a vascular disease produced by an anti-angiogenic environment in late pregnancy..PubMedCrossRef
14.
Zurück zum Zitat Midei MG, DeMent SH, Feldman AM, Hutchins GM, Baughman KL. Peripartum myocarditis and cardiomyopathy. Circulation. 1990;81:922–8.PubMedCrossRef Midei MG, DeMent SH, Feldman AM, Hutchins GM, Baughman KL. Peripartum myocarditis and cardiomyopathy. Circulation. 1990;81:922–8.PubMedCrossRef
15.
Zurück zum Zitat Sliwa K, Skudicky D, Candy G, Bergemann A, Hopley M, Sareli P. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2002;4:305–9.PubMedCrossRef Sliwa K, Skudicky D, Candy G, Bergemann A, Hopley M, Sareli P. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2002;4:305–9.PubMedCrossRef
16.
Zurück zum Zitat van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation. 2010;121:2169–75.PubMedCrossRef van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation. 2010;121:2169–75.PubMedCrossRef
17.
Zurück zum Zitat Morales A, Painter T, Li R, et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation. 2010;121:2176–82.PubMedCrossRef Morales A, Painter T, Li R, et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation. 2010;121:2176–82.PubMedCrossRef
18.
Zurück zum Zitat Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J. 2006;152:509–13.PubMedCrossRef Amos AM, Jaber WA, Russell SD. Improved outcomes in peripartum cardiomyopathy with contemporary. Am Heart J. 2006;152:509–13.PubMedCrossRef
19.
Zurück zum Zitat Goland S, Bitar F, Modi K, et al. Evaluation of the clinical relevance of baseline left ventricular ejection fraction as a predictor of recovery or persistence of severe dysfunction in women in the United States with peripartum cardiomyopathy. J Card Fail. 2011;17:426–30.PubMedCrossRef Goland S, Bitar F, Modi K, et al. Evaluation of the clinical relevance of baseline left ventricular ejection fraction as a predictor of recovery or persistence of severe dysfunction in women in the United States with peripartum cardiomyopathy. J Card Fail. 2011;17:426–30.PubMedCrossRef
20.
21.
Zurück zum Zitat Cooper LT, Mather PJ, Alexis JD, et al. Myocardial recovery in peripartum cardiomyopathy: prospective comparison with recent onset cardiomyopathy in men and nonperipartum women. J Card Fail. 2012;18:28–33.PubMedCrossRef Cooper LT, Mather PJ, Alexis JD, et al. Myocardial recovery in peripartum cardiomyopathy: prospective comparison with recent onset cardiomyopathy in men and nonperipartum women. J Card Fail. 2012;18:28–33.PubMedCrossRef
22.
Zurück zum Zitat Safirstein JG, Ro AS, Grandhi S, Wang L, Fett JD, Staniloae C. Predictors of left ventricular recovery in a cohort of peripartum cardiomyopathy patients recruited via the internet. Int J Cardiol. 2010;154:27–31.PubMedCrossRef Safirstein JG, Ro AS, Grandhi S, Wang L, Fett JD, Staniloae C. Predictors of left ventricular recovery in a cohort of peripartum cardiomyopathy patients recruited via the internet. Int J Cardiol. 2010;154:27–31.PubMedCrossRef
23.
Zurück zum Zitat Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077–84.PubMedCrossRef Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077–84.PubMedCrossRef
24.
Zurück zum Zitat Modi KA, Illum S, Jariatul K, Caldito G, Reddy PC. Poor outcome of indigent patients with peripartum cardiomyopathy in the United States. Am J Obstet Gynecol. 2009;201:171 e1–5.CrossRef Modi KA, Illum S, Jariatul K, Caldito G, Reddy PC. Poor outcome of indigent patients with peripartum cardiomyopathy in the United States. Am J Obstet Gynecol. 2009;201:171 e1–5.CrossRef
26.
Zurück zum Zitat McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847.PubMedCrossRef McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847.PubMedCrossRef
27.
Zurück zum Zitat Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391–479.PubMedCrossRef Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:e391–479.PubMedCrossRef
28.
Zurück zum Zitat Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;16:e1–e194.PubMedCrossRef Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;16:e1–e194.PubMedCrossRef
29.
Zurück zum Zitat Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–89.CrossRef Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–89.CrossRef
30.•
Zurück zum Zitat Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797–805. A randomized study of acute decompensated heart failure patients showing that either bolus or continuous loop diuretic at high or low dose could successfully relieve congestion..PubMedCrossRef Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797–805. A randomized study of acute decompensated heart failure patients showing that either bolus or continuous loop diuretic at high or low dose could successfully relieve congestion..PubMedCrossRef
31.
Zurück zum Zitat Shotan A, Widerhorn J, Hurst A, Elkayam U. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med. 1994;96:451–6.PubMedCrossRef Shotan A, Widerhorn J, Hurst A, Elkayam U. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med. 1994;96:451–6.PubMedCrossRef
32.•
Zurück zum Zitat Biteker M, Ilhan E, Biteker G, Duman D, Bozkurt B. Delayed recovery in peripartum cardiomyopathy: an indication for long-term follow-up and sustained therapy. Eur J Heart Fail. 2012;14:895–901. A prospective study showing that ventricular recovery after PPCM often takes longer than 6 months..PubMedCrossRef Biteker M, Ilhan E, Biteker G, Duman D, Bozkurt B. Delayed recovery in peripartum cardiomyopathy: an indication for long-term follow-up and sustained therapy. Eur J Heart Fail. 2012;14:895–901. A prospective study showing that ventricular recovery after PPCM often takes longer than 6 months..PubMedCrossRef
33.
Zurück zum Zitat Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–57.PubMedCrossRef Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–57.PubMedCrossRef
34.
35.
Zurück zum Zitat Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.PubMedCrossRef Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.PubMedCrossRef
36.
Zurück zum Zitat Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543–51.PubMedCrossRef Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004;351:543–51.PubMedCrossRef
37.
Zurück zum Zitat The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–33.CrossRef The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–33.CrossRef
38.
Zurück zum Zitat Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289:871–8.PubMedCrossRef Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289:871–8.PubMedCrossRef
39.
Zurück zum Zitat Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003;29:125–30.PubMedCrossRef Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003;29:125–30.PubMedCrossRef
40.
Zurück zum Zitat James AH, Brancazio LR, Ortel TL. Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy. Clin Adv Hematol Oncol. 2005;3:187–97.PubMed James AH, Brancazio LR, Ortel TL. Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy. Clin Adv Hematol Oncol. 2005;3:187–97.PubMed
41.
Zurück zum Zitat Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117:e350–408.PubMedCrossRef Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117:e350–408.PubMedCrossRef
42.
Zurück zum Zitat Saltzberg MT, Szymkiewicz S, Bianco NR. Characteristics and outcomes of peripartum vs nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator. J Card Fail. 2012;18:21–7.PubMedCrossRef Saltzberg MT, Szymkiewicz S, Bianco NR. Characteristics and outcomes of peripartum vs nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator. J Card Fail. 2012;18:21–7.PubMedCrossRef
43.
Zurück zum Zitat Mouquet F, Mostefa Kara M, Lamblin N, et al. Unexpected and rapid recovery of left ventricular function in patients with peripartum cardiomyopathy: impact of cardiac resynchronization therapy. Eur J Heart Fail. 2012;14:526–9.PubMedCrossRef Mouquet F, Mostefa Kara M, Lamblin N, et al. Unexpected and rapid recovery of left ventricular function in patients with peripartum cardiomyopathy: impact of cardiac resynchronization therapy. Eur J Heart Fail. 2012;14:526–9.PubMedCrossRef
44.
Zurück zum Zitat Stevenson WG, Hernandez AF, Carson PE, et al. Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee. J Card Fail. 2011;18:94–106.CrossRef Stevenson WG, Hernandez AF, Carson PE, et al. Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee. J Card Fail. 2011;18:94–106.CrossRef
45.
Zurück zum Zitat Gevaert S, Van Belleghem Y, Bouchez S, et al. Acute and critically ill peripartum cardiomyopathy and 'bridge to' therapeutic options: a single center experience with intra-aortic balloon pump, extra corporeal membrane oxygenation, and continuous-flow left ventricular assist devices. Crit Care. 2011;15:R93.PubMedCrossRef Gevaert S, Van Belleghem Y, Bouchez S, et al. Acute and critically ill peripartum cardiomyopathy and 'bridge to' therapeutic options: a single center experience with intra-aortic balloon pump, extra corporeal membrane oxygenation, and continuous-flow left ventricular assist devices. Crit Care. 2011;15:R93.PubMedCrossRef
46.
Zurück zum Zitat Zimmerman H, Bose R, Smith R, Copeland JG. Treatment of peripartum cardiomyopathy with mechanical assist devices and cardiac transplantation. Ann Thorac Surg. 2010;89:1211–7.PubMedCrossRef Zimmerman H, Bose R, Smith R, Copeland JG. Treatment of peripartum cardiomyopathy with mechanical assist devices and cardiac transplantation. Ann Thorac Surg. 2010;89:1211–7.PubMedCrossRef
47.
Zurück zum Zitat Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–51.PubMedCrossRef Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–51.PubMedCrossRef
48.
Zurück zum Zitat Habli M, O'Brien T, Nowack E, Khoury S, Barton JR, Sibai B. Peripartum cardiomyopathy: prognostic factors for long-term maternal outcome. Am J Obstet Gynecol. 2008;199:415e1–5. Habli M, O'Brien T, Nowack E, Khoury S, Barton JR, Sibai B. Peripartum cardiomyopathy: prognostic factors for long-term maternal outcome. Am J Obstet Gynecol. 2008;199:415e1–5.
49.
Zurück zum Zitat Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates–2006. J Heart Lung Transplant. 2006;25:1024–42.PubMedCrossRef Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates–2006. J Heart Lung Transplant. 2006;25:1024–42.PubMedCrossRef
50.••
Zurück zum Zitat Rasmusson K, Brunisholz K, Budge D, et al. Peripartum cardiomyopathy: post-transplant outcomes from the United Network for Organ Sharing Database. J Heart Lung Transplant. 2012;31:180–6. A large report showing that rejection and graft failure are more likely in PPCM compared with other transplant recipients, which may be explained by higher degrees of sensitization and higher pre-transplant acuity..PubMedCrossRef Rasmusson K, Brunisholz K, Budge D, et al. Peripartum cardiomyopathy: post-transplant outcomes from the United Network for Organ Sharing Database. J Heart Lung Transplant. 2012;31:180–6. A large report showing that rejection and graft failure are more likely in PPCM compared with other transplant recipients, which may be explained by higher degrees of sensitization and higher pre-transplant acuity..PubMedCrossRef
51.
Zurück zum Zitat Ecker JL, Frigoletto Jr FD. Cesarean delivery and the risk-benefit calculus. N Engl J Med. 2007;356:885–8.PubMedCrossRef Ecker JL, Frigoletto Jr FD. Cesarean delivery and the risk-benefit calculus. N Engl J Med. 2007;356:885–8.PubMedCrossRef
52.
Zurück zum Zitat Blauwet LA, Cooper LT. Diagnosis and management of peripartum cardiomyopathy. Heart. 2011;97:1970–81.PubMedCrossRef Blauwet LA, Cooper LT. Diagnosis and management of peripartum cardiomyopathy. Heart. 2011;97:1970–81.PubMedCrossRef
53.
Zurück zum Zitat Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med. 2001;344:1567–71.PubMedCrossRef Elkayam U, Tummala PP, Rao K, et al. Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med. 2001;344:1567–71.PubMedCrossRef
54.
Zurück zum Zitat Yamac H, Bultmann I, Sliwa K, Hilfiker-Kleiner D. Prolactin: a new therapeutic target in peripartum cardiomyopathy. Heart. 2010;96:1352–7.PubMedCrossRef Yamac H, Bultmann I, Sliwa K, Hilfiker-Kleiner D. Prolactin: a new therapeutic target in peripartum cardiomyopathy. Heart. 2010;96:1352–7.PubMedCrossRef
55.•
Zurück zum Zitat Walenta K, Schwarz V, Schirmer SH, et al. Circulating microparticles as indicators of peripartum cardiomyopathy. Eur Heart J. 2012;33:1469–79. This study demonstrated that circulating microparticles can be quantified and used to distinguish PPCM from normal pregnancy, heart failure, and other vascular diseases, pacing the way for microparticle profile as a potential biomarker for PPCM..PubMedCrossRef Walenta K, Schwarz V, Schirmer SH, et al. Circulating microparticles as indicators of peripartum cardiomyopathy. Eur Heart J. 2012;33:1469–79. This study demonstrated that circulating microparticles can be quantified and used to distinguish PPCM from normal pregnancy, heart failure, and other vascular diseases, pacing the way for microparticle profile as a potential biomarker for PPCM..PubMedCrossRef
56.••
Zurück zum Zitat Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation. 2010;121:1465–73. Important proof-of-concept study demonstrating that oral bromocriptine, which blocks prolactin release, is associated with improved ventricular recovery compared with placebo..PubMedCrossRef Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation. 2010;121:1465–73. Important proof-of-concept study demonstrating that oral bromocriptine, which blocks prolactin release, is associated with improved ventricular recovery compared with placebo..PubMedCrossRef
57.
Zurück zum Zitat Fett JD. Caution in the use of bromocriptine in peripartum cardiomyopathy. J Am Coll Cardiol. 2008;51:2083.PubMedCrossRef Fett JD. Caution in the use of bromocriptine in peripartum cardiomyopathy. J Am Coll Cardiol. 2008;51:2083.PubMedCrossRef
58.
Metadaten
Titel
Management of Peripartum Cardiomyopathy
verfasst von
Garrick C. Stewart, MD
Publikationsdatum
01.12.2012
Verlag
Current Science Inc.
Erschienen in
Current Treatment Options in Cardiovascular Medicine / Ausgabe 6/2012
Print ISSN: 1092-8464
Elektronische ISSN: 1534-3189
DOI
https://doi.org/10.1007/s11936-012-0210-9

Weitere Artikel der Ausgabe 6/2012

Current Treatment Options in Cardiovascular Medicine 6/2012 Zur Ausgabe

Valvular Heart Disease (AS Desai and PT O'Gara, Section Editors)

Diagnosis and Management of Ebstein Anomaly of the Tricuspid Valve

Valvular Heart Disease (AS Desai and PT O'Gara, Section Editors)

Cardiac Sarcoidosis: Diagnosis and Management

Valvular Heart Disease (AS Desai and PT O'Gara, Section Editors)

Management of Asymptomatic, Severe Mitral Regurgitation

Valvular Heart Disease (AS Desai and PT O’Gara, Section Editors)

Minimally Invasive Surgery for Valvular Heart Disease

Valvular Diseases (AS Desai and PT O’Gara, Section Editor)

Myocarditis: Diagnosis and Treatment

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.